The NHS Sickle Cell and Thalassaemia (SCT) screening programme is a genetic screening programme. This means that it also identifies people who are genetic carriers for sickle cell, thalassaemia and other haemoglobin disorders.
The aim of our epidemiology, statistics, and outcomes research is to increase our understanding of the causes of cancer as well as to develop better strategies for diagnosing, treating, and preventing disease.
West Midlands Quality Review Service is a collaborative venture by NHS organisations in the West Midlands to improve the quality of health services by undertaking reviews of the quality of clinical services
The National Haemoglobinopathy Registry is a database of patients with red cell disorders living in the UK. This new database collects data,which is required by the Department of Health from Haemoglobinopathy centres. The central aim of the registry is to improve patient care.
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. Our guidance, advice, quality standards and information services for health, public health and social care. Also contains resources to help maximise use of evidence and guidance.
This Clinical Reference Group (CRG) covers Sickle Cell Disease (SCD), Thalassaemia and other very rare anaemias requiring lifelong transfusion and chelation. Haemoglobinopathies are complex disorders which although often grouped together and managed by the same specialist team, have distinct clinical manifestations and treatments.